A 60-week, multicentre, randomised, double-blind study of subcutaneous secukinumab to demonstrate efficacy as assessed by Psoriasis Area and Severity Index at 28 weeks of treatment compared to Ustekinumab and to assess long term safety, tolerability and efficacy in subjects with moderate to severe chronic plaque-type psoriasis

Trial Profile

A 60-week, multicentre, randomised, double-blind study of subcutaneous secukinumab to demonstrate efficacy as assessed by Psoriasis Area and Severity Index at 28 weeks of treatment compared to Ustekinumab and to assess long term safety, tolerability and efficacy in subjects with moderate to severe chronic plaque-type psoriasis

Completed
Phase of Trial: Phase III

Latest Information Update: 16 Jun 2016

At a glance

  • Drugs Secukinumab (Primary) ; Ustekinumab
  • Indications Plaque psoriasis
  • Focus Registrational; Therapeutic Use
  • Sponsors Novartis Pharmaceuticals Corporation
  • Most Recent Events

    • 30 Mar 2016 Status changed from active, no longer recruiting to completed.
    • 22 Aug 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top